Blood levels of some amino acids tied to lower Parkinson’s risk

Altered BCAA metabolism may suggest disease years before diagnosis

Written by Andrea Lobo |

A graphic image shows molecules floating in a liquid environment.

Blood levels of certain amino acids may point to Parkinson's risk. (Image by iStock)

  • Higher blood levels of branched-chain amino acids (BCAAs) are associated with a reduced risk of developing Parkinson's disease.
  • Altered BCAA metabolism and decreased levels may appear years before a formal Parkinson's diagnosis.
  • Further research and clinical trials are required to determine if modifying BCAA metabolism offers preventive benefits.

Higher blood levels of certain branched-chain amino acids (BCAAs) — essential amino acids the body obtains from food and uses to build proteins — may be associated with a lower risk of developing Parkinson’s disease, according to an analysis of UK Biobank data.

The analysis also linked these amino acids to differences in biological aging, blood biomarkers of neurological damage, and nerve fiber structure, suggesting that changes in BCAA metabolism may be detectable years before a Parkinson’s diagnosis.

“These findings suggest that altered BCAA metabolism may represent a prediagnostic metabolic feature of [Parkinson’s disease] and support further investigation of its biological and translational relevance,” the researchers wrote.

The study, “Circulating branched-chain amino acids and multimodal signatures of incident Parkinson’s disease: a prospective cohort study,” was published in npj Parkinson’s Disease.

Parkinson’s is caused by the loss of nerve cells that produce dopamine, a signaling molecule involved in motor control. Although its causes aren’t fully understood, age-related changes, inflammation, and metabolic disturbances may contribute to disease development.

Recommended Reading
new column banner

Strategies for navigating the inner journey of Parkinson’s disease

Exploring BCAAs

BCAAs — leucine, isoleucine, and valine — are essential amino acids that the body obtains through food. They contribute to protein production, energy metabolism, and cellular signaling, and may influence processes involved in brain function.

Previous studies have reported altered BCAA levels in people with Parkinson’s, but it has not been clear whether these changes emerge before diagnosis or result from disease progression, changes in diet, or other factors.

To learn more, researchers analyzed data from 374,751 UK Biobank participants who did not have Parkinson’s or other neurodegenerative diseases at baseline. The UK Biobank is a comprehensive dataset of biological, medical, and lifestyle information.

During follow-up, 2,838 participants developed Parkinson’s. Participants who developed Parkinson’s were significantly older (median age 64 vs. 58) and more often male (63.2% vs. 45.9%) than those who did not develop the disease.

They also had a higher Parkinson’s disease polygenic risk score, a measure of a person’s genetic susceptibility to the disease, and a higher burden of metabolic diseases, including high blood pressure, diabetes, stroke, and coronary heart disease (a condition caused by reduced blood flow to the heart). Unadjusted baseline BCAA blood levels were slightly higher among participants who subsequently developed Parkinson’s, which could be driven by factors such as older age and higher male representation.

After adjusting for demographic, lifestyle, genetic, and metabolic factors, participants with moderately and highly elevated BCAA levels had a 12% and 17% lower risk of developing Parkinson’s, respectively, than those with low levels. Participants with the highest leucine levels had a 13% lower risk, while moderate and high valine levels were associated with 10% and 17% lower risks, respectively.

Higher BCAA levels were associated with a lower risk of Parkinson’s disease in adults aged 60 and older, but not in younger adults. Some associations were also observed in women and people with lower genetic risk. However, statistical tests did not provide clear evidence that age, sex, or genetic risk changed the relationship between BCAA levels and Parkinson’s risk.

People who later developed Parkinson’s tended to have lower blood levels of BCAAs in the years leading up to their diagnosis. These differences became noticeable about five to seven years before diagnosis. However, the study did not track changes in BCAA levels over time in the same people.

Higher blood levels of BCAAs were also linked to healthier brain scans and lower blood levels of two proteins tied to brain stress and damage: GFAP, a sign of immune-like support cell activity, and neurofilament light chain, a marker of nerve fiber injury.

Higher levels of total BCAAs, leucine, and valine were associated with lower biological age acceleration, suggesting these changes may reflect “a slower biological aging process,” the researchers wrote.

These findings place “BCAA dysregulation within broader … biomarkers detectable during the prediagnostic phase of [Parkinson’s disease],” they added.

The study does not establish that higher BCAA levels protect against Parkinson’s or that increasing their intake would prevent the disease. BCAAs were measured only once, in blood, so the researchers could not track changes over time or determine how these amino acids behave in the brain.

Future studies incorporating repeated metabolic measurements, detailed molecular analyses, and mechanistic experiments are needed to clarify how BCAAs relate to Parkinson’s development, the researchers said. Clinical intervention studies would also be required to determine whether modifying BCAA metabolism could be beneficial.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.